Questions - answers on the use of rivaroxaban for the treatment of venous thromboembolic disease;Questions - réponses sur l'utilisation du rivaroxaban pour le traitement de la maladie thromboembolique veineuse

Journal des Maladies Vasculaires

Volumn 37, Issue 6, 2012, Pages 300-310

  Pernod, G ^a   Elias, A ^b   Gouin, I ^c   Gaillard, C ^d   Nguyen, P ^e   Ouvry, P ^d   Sie P ^f  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b Centre Hospitalier Intercommunal Toulon La Seyne sur Mer   (France)

^c HÔTEL DIEU   (France)

^d Cabinet de médecine vasculaire   (France)

^e REIMS UNIVERSITY HOSPITAL   (France)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Deep vein thrombosis; Rivaroxaban

Indexed keywords

RIVAROXABAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE; VITAMIN;

CLINICAL PRACTICE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; SECONDARY PREVENTION; SHORT SURVEY; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; AGE; ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG INTERACTION; FRANCE; RISK FACTOR; VEIN THROMBOSIS;

AGE FACTORS; ANTICOAGULANTS; DRUG INTERACTIONS; FACTOR XA; FRANCE; HEMORRHAGE; HUMANS; MORPHOLINES; PULMONARY EMBOLISM; RISK FACTORS; THIOPHENES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; VITAMINS;

EID: 84870389772     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmv.2012.09.003     Document Type: Short Survey

References (19)

1. The EINSTEIN investigators, Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
2. The EINSTEIN-PE Investigators, Büller H.R., Prins M.H., Lensin A.W., Decousus H., Jacobson B.F., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297.
3. Kubitza D., Becka M., Wensing G., Voith B., Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61:873-880.
4. Agnelli G., Gallus A., Goldhaber S.Z., Haas S., Huisman M.V., Hull R.D., et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007, 116:180-187.
5. Buller H.R., Lensing A.W., Prins M.H., Agnelli G., Cohen A., Gallus A.S., et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008, 112:2242-2247.
6. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
7. Mega J.L., Braunwald E., Wiviott S.D., Bassand J.P., Bhatt D.L., Bode C., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19.
8. Sie P., Samama C.M., Godier A., Rosencher N., Steib A., Llau J.V., et al. Surgery and Invasive procedures. Ann Fr Anesth Reanim 2011, 30:645-650.
9. Pernod G., Godier A., Gozalo C., Tremey B., Sié P. French National Authority for Health. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010, 126:e167-e174.
10. Girerd X., Hanon O., Anangnostopoulos K., Cirepek L., Mourad J.J., Consoli S. Evaluation de l'observance du traitement antihypertenseur par un questionnaire: mise au point et utilisation dans un service spécialisé Presse Med 2001, 30:1044-1048.
11. Hillarp A., Baghaei F., Fagerberg Blixter I., Gustafsson K.M., Stigendal L., Sten-Linder M., et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011, 9:133-139.
12. Perzborn E., Stassburger J., Wilmen A., Pohlmann J., Roehrig S., Schlemmer K.H., et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939- an oral, direct factor Xa inhibitor. J Thromb Haemost 2004, 3:514-521.
13. Tripodi A., Chantarangkul V., Guinet C., Samama M.M. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 2011, 9:226-228.
14. Samama M.M., Martinoli J.L., LeFlem L., Guinet C., Plu-Bureau G., Depasse F., et al. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825.
15. Gerotziafas G.T., Baccouche H., Sassi M., Galea V., Chaari M., Hatmi M., et al. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res 2012, 129:101-103.
16. Marlu R., Hodaj E., Paris A., Albaladejo P., Crackowski J.L., Pernod G. Effect of non-specific reversal agents on anticoagulant activity of Dabigatran and Rivaroxaban: a randomised crossover ex-vivo study in healthy volunteers. Thromb Haemost 2012, 108:217-224.
17. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
18. Mueck W., Lensing A.W.A., Agnelli G., Decousus H., Prandoni P., Misselwitz F. Rivaroxaban. Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulation in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011, 50:675-686.
19. Freyburger G., Macouillard G., Labrouche S., Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011, 127:457-465.